New TPO treatment schedules of increased safety and efficacy: Pre-clinical validation of a thrombopoiesis simulation model

British Journal of Haematology

Volumn 123, Issue 4, 2003, Pages 683-691

  Skomorovski, Kirill ^a   Harpak, Hila ^a   Ianovski, Anton ^b   Vardi, Moshe ^b   Visser, Trudi P ^c   Hartong, Simone C C ^c   Van Vliet, Huub H D M ^c   Wagemakers, Gerard ^c   Agur, Zvia ^a,b  

^a Institute for Medical Biomathematics Isarel   (Israel)

^b Optimata Ltd   (Israel)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Immunogenicity; Modelling; Thrombopoiesis; Thrombopoietin; Treatment schedule

Indexed keywords

RECOMBINANT THROMBOPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STIMULATION; COMPARATIVE STUDY; COMPUTER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EXPERIMENTAL MODEL; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RHESUS MONKEY; SIMULATION; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; VALIDATION PROCESS;

ANIMALS; CALIBRATION; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; MACACA MULATTA; MALE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; PLATELET COUNT; RANDOM ALLOCATION; THROMBOPOIESIS; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 0344530245     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04696.x     Document Type: Article

References (32)

1. Agur, Z., Arnon, R. & Schechter, B. (1988) Reduction of cytotoxicity to normal tissues by new regimens of phase-specific drugs. Mathematical Biosciences, 92, 1-15.
2. Agur, Z., Arnon, R., Sandak, B. & Schechter, B. (1991) Zidovudine toxicity to murine bone marrow may be affected by the exact frequency of drug administration. Experimental Hematology, 19, 364-368.
3. Arnold, J.T., Daw, N.C., Stenberg, P.E., Jayawardene, D., Srivastava, D.K. & Jackson, C.W. (1997) A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size, and ploidization. Blood, 89, 823-833.
4. Basser, R. (2002) The impact of thrombopoietin on clinical practice. Current Pharmaceutical Design, 8, 369-377.
5. Brent, R.P. (1973) Algorithms for Minimization Without Derivatives. Prentice-Hall, Englewood Cliffs, NJ.
6. Daw, N.C., Arnold, J.T., Abushullaih, B.A., Stenberg, P.E., White, M.M., Jayawardene, D., Srivastava, D.K. & Jackson, C.W. (1998) A single intravenous dose of murine megakaryocyte growth and development factor potently stimulates platelet production, challenging the necessity for daily administration. Blood, 91, 466-474.
7. De Serres, M., Yeager, R.L., Dillberger, J.E., Lalonde, G., Gardner, G.H., Rubens, C.A., Simkins, A.H., Sailstad, J.M., McNulty, M.J. & Woolley, J.L. (1999) Pharmacokinetics and hematological effects of the pegylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration. Stem Cells, 17, 316-326.
8. Demetri, G.D. (2001) Targeted approaches for the treatment of thrombocytopenia. The Oncologist, 6(Suppl. 5), 15-23.
9. Ebbe, S. & Stohlman, F. (1965) Megakaryocytopoiesis in the rat. Blood, 26, 20-35.
10. Elting, L.S., Rubenstein, E.B., Martin, C.G., Kurtin, D., Rodriguez, S., Laiho, E., Kanesan, K., Cantor, S.B. & Benjamin, R.S. (2001) Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. Journal of Clinical Oncology, 19, 1137-1146.
11. Farese, A.M., Hunt, P., Boone, T. & MacVittie, T.J. (1995) Recombinant human megakaryocyte growth and development factor stimulates thrombopoiesis in normal nonhuman primates. Blood, 86, 54-59.
12. Harker, L.A. (1999) Physiology and clinical applications of platelet growth factors. Current Opinion in Hematology, 6, 127-134.
13. Harker, L.A., Hunt, P., Marzec, U.M., Kelly, A.B., Tomer, A., Hanson, S.R. & Stead, R.B. (1996a) Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood, 87, 1833-1844.
14. Harker, L.A., Marzec, U.M., Hunt, P., Kelly, A.B., Tomer. A., Cheung, E., Hanson, S.R. & Stead, R.B. (1996b) Dose-response effects of pegylated human megakaryocyte growth and development factor of platelet production and function in nonhuman primates. Blood, 88, 511-521.
15. Haznedaroglu, I.C., Goker, H., Turgut, M., Buyukasik, Y. & Benekli, M. (2002) Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions. Clinical and Applied Thrombosis/Hemostasis. 8, 193-212.
16. Kabaya, K., Akahori, H., Shibuya, K., Nitta, Y., Ida, M., Kusaka, M., Kato, T. & Miyazaki, H. (1996) In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. Stem Cells, 14, 651-660.
17. Kaushansky, K., Lin, N., Grossman, A., Humes, J., Sprugel, K.H. & Broudy, V.C. (1996) Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Experimental Hematology. 24, 265-269.
18. Luoh, S., Stephanich, E., Solar, G., Steinmetz, H., Lipari, T., Pestina, T.I., Jackson, C.W. & de Sauvage, F.J. (2000) Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo. Molecular and Cellular Biology, 20, 507-515.
19. Miyazaki, M., Fujiwara, Y., Isobe, T., Yamakido, M., Kato, T. & Miyazaki, H. (1999) The relationship between carboplatin AUC and serum TPO kinetics in patients with lung cancer. Anticancer Research, 19, 667-670.
20. Neelis, K.J., Qingliang, L., Thomas, G.R., Cohen, B.L., Eaton, D.L. & Wagemaker, G. (1997a) Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion. Blood, 90, 58-63.
21. Neelis, K.J., Hartong, S.C., Egeland, T., Thomas, G.R., Eaton, D.L. & Wagemaker, G. (1997b) The efficacy of single-dose administration of thrombopoietin with co-administration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys. Blood, 90, 2565-2573.
22. Neelis, K.J., Visser, T.P., Dimjati, W., Thomas, G.R., Fielder, P.J., Bloedow, D., Eaton, D.L. & Wagemaker, G. (1998) A single dose of TPO shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multi-lineage spleen-repopulating cells at the transient expense of bone marrow-repopulating cells. Blood, 92, 1586-1597.
23. Press, W.H., Flannery, B.P., Teukolsky, S.A. & Vetterling, W.T. (1993) Numerical Recipes in C: The Art of Scientific Computing. Cambridge University Press, Cambridge, UK.
24. Schermer, S. (1967) The Blood Morphology of Laboratory Animals. F.A. Davis Co., Philadelphia, PE.
25. Siegers, M.P., Feinendegen, L.E., Lahiri, S.K. & Cronkite, E.P. (1979) Relative number and proliferation kinetics of hemopoietic stem cells in the mouse. Blood cells, 5, 211-236.
26. Skomorovski, K. & Agur, Z. (2001) A new method for predicting and optimizing thrombopoietin (TPO) therapeutic protocols in thrombocytopenic patients and in platelet donors [abstract]. The Hematology Journal, 1(Suppl. 1), 185.
27. Sola, M.C., Christensen, R.D., Hutson, A.D. & Tarantal, A.F. (2000) Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys. Pediatric Research, 47, 208-214.
28. Ubezio, P., Tagliabue, G., Schechter, B. & Agur, Z. (1994) Increasing 1-beta-D-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics. Cancer Research, 54, 6446-6451.
29. Ulich, T.R., del Castillo, J., Senaldi, G., Cheung, E., Roskos, L., Young, J., Molineux, G., Guo, J., Schoemperlen, J., Munyakazi, L., Murphy-Filkins, R., Tarpley, J.E., Toombs, C.F., Kaufman, S., Yin, S., Nelson, A.G., Nichol, J.L. & Sheridan, W.P. (1999) Megakaryocytopoiesis: the prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice. Experimental Hematology, 27, 117-130.
30. Vadhan-Raj, S. (1998) Recombinant human TPO: clinical experience and in vivo biology. Seminars in Hematology, 35, 261-268.
31. Vadhan-Raj, S., Murray, L.J., Bueso-Ramos, C., Patel, S., Reddy, S.P., Hoots, W.K., Johnston, T., Papadopolous, N.E., Hittelman, W.N., Johnston, D.A., Yang, T.A., Paton, V.E., Cohen, R.L., Hellmann, S.D., Benjamin, R.S. & Broxmeyer, H.E. (1997) Stimulation of megakaryocyte and platelet production by a single dose of recombinant human TPO in patients with cancer. Annals of Internal Medicine, 126, 673-681.
32. Wagemaker, G., Hartong, S.C., Neelis, K.J., Egeland, T. & Wognum, A.W. (1998) In vivo expansion of hemopoietic stem cells. Stem Cells, 16(Suppl. 1), 185-191.